Korea BNC Signs Exclusive Manufacturing and Sales License Agreement for COVID-19 Treatment in 4 Countries
[Asia Economy Reporter Park Junyi] Korea BNC announced on the 4th that it has signed an exclusive manufacturing and sales license agreement for the COVID-19 treatment Antroquinonol (Hocena) in four countries. The contract period is 10 years from the date of the agreement.
Hot Picks Today
After Topping 8,000 Instead of Hitting 10,000... KOSPI Plunges—When Will It Rebound?
- "Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- [Breaking] Court Rules Against Samsung Electronics Union...1 Billion Won per Day Penalty for Exceeding Strike Scope
- Stronger Fines for Personal Data Leaks Start Tomorrow... Higher Sales Standards Applied
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
